- Home
- CSBR vs IDE Comparison
CSBR vs IDE Comparison
Compare CSBR & IDE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CSBR
- IDE
- Stock Information
- Founded
- CSBR 1985
- IDE 2010
- Country
- CSBR United States
- IDE United States
- Employees
- CSBR N/A
- IDE N/A
- Industry
- CSBR Biotechnology: Biological Products (No Diagnostic Substances)
- IDE Finance/Investors Services
- Sector
- CSBR Health Care
- IDE Finance
- Exchange
- CSBR Nasdaq
- IDE Nasdaq
- Market Cap
- CSBR 113.0M
- IDE N/A
- IPO Year
- CSBR 1986
- IDE N/A
- Fundamental
- Price
- CSBR $7.90
- IDE $10.45
- Analyst Decision
- CSBR Strong Buy
- IDE
- Analyst Count
- CSBR 1
- IDE 0
- Target Price
- CSBR $12.00
- IDE N/A
- AVG Volume (30 Days)
- CSBR 36.4K
- IDE 33.5K
- Earning Date
- CSBR 03-11-2025
- IDE 01-01-0001
- Dividend Yield
- CSBR N/A
- IDE 8.83%
- EPS Growth
- CSBR N/A
- IDE N/A
- EPS
- CSBR 0.46
- IDE N/A
- Revenue
- CSBR $58,591,000.00
- IDE N/A
- Revenue This Year
- CSBR $15.11
- IDE N/A
- Revenue Next Year
- CSBR $7.80
- IDE N/A
- P/E Ratio
- CSBR $17.27
- IDE N/A
- Revenue Growth
- CSBR 19.03
- IDE N/A
- 52 Week Low
- CSBR $3.60
- IDE $8.61
- 52 Week High
- CSBR $11.99
- IDE $10.46
- Technical
- Relative Strength Index (RSI)
- CSBR 43.84
- IDE 56.46
- Support Level
- CSBR $7.61
- IDE $9.89
- Resistance Level
- CSBR $8.86
- IDE $10.22
- Average True Range (ATR)
- CSBR 0.69
- IDE 0.31
- MACD
- CSBR 0.04
- IDE 0.08
- Stochastic Oscillator
- CSBR 44.28
- IDE 97.70
About CSBR Champions Oncology Inc.
Champions Oncology Inc is a USA based company which is engaged in the development and sale of state of the art technology solutions and products to personalize the development and use of oncology drugs. The company operates through one segment namely Personalized Oncology Solutions (POS) and Translational Oncology Solutions (TOS). Its POS business assists physicians in developing personalized treatment options for their cancer patients through tumor-specific data obtained from drug panels and related personalized oncology services. The TOS business assists pharmaceutical and biotechnology companies with their drug development process and offers studies or license tumors for use in studies. The company's revenue is majorly derived from research services.